未治疗的特发性突发性感音神经性听力损失的自然史
该研究为系统综述与Meta分析,纳入6项研究共319例未治疗或安慰剂治疗的特发性突发性感音神经性听力损失成人患者,评估其听力转归的自然史。结果显示3个月时36%患者听力改善至少30 dB HL,70%改善至少10 dB HL,2-3个月平均听力增益24.0 dB HL。作者认为这些数据可作为历史对照,并呼吁开展多机构随机双盲安慰剂对照试验。
要点
- 未治疗的特发性突发性感音神经性听力损失患者中,36%(95% CI 0.28-0.44)在3个月时听力改善至少30 dB HL。
- 70%(95% CI 0.57-0.82)的未治疗患者在3个月时听力改善至少10 dB HL。
- 未治疗患者2-3个月的平均听力增益为24.0 dB HL(95% CI 2.65-45.37)。
核心结论
- 观察到的自然史提示特发性突发性感音神经性听力损失患者可在无主动治疗下恢复部分听力。
- 在缺乏未来收集未治疗或安慰剂治疗患者前瞻性自然史数据的研究情况下,本文数据为重新审视既往研究和设计未来临床试验提供了最佳历史对照数据。
- 未治疗/安慰剂组存在有统计学意义的平均听力增益24.0 dB HL,为未来安慰剂研究提供了伦理依据。
- 当前特发性突发性感音神经性听力损失的管理现状呼吁开展多机构、随机、双盲、安慰剂对照试验,采用经验证的结局指标,以提供基于科学的治疗指导。
研究设计与样本
- 系统综述与Meta分析,检索PubMed、Scopus、Web of Science和Cochrane Library数据库截至2022年6月30日的文献。
- 纳入所有研究类型中接受安慰剂或未治疗且有听力学结局指标的成人特发性突发性感音神经性听力损失患者。
- 共纳入6项研究,319例未治疗患者可评估自然史。
- 采用I²评估异质性并进行随机效应分析。
主要发现
- 研究间异质性为中等,报告了多种结局。
- 未治疗患者3个月时听力改善至少30 dB HL的比例为36%(95% CI 0.28-0.44)。
- 未治疗患者3个月时听力改善至少10 dB HL的比例为70%(95% CI 0.57-0.82)。
- 未治疗患者2-3个月的平均听力增益为24.0 dB HL(95% CI 2.65-45.37)。
关键数值与推荐
- 未治疗患者3个月时听力改善至少30 dB HL的比例为36%(95% CI 0.28-0.44)。
- 未治疗患者3个月时听力改善至少10 dB HL的比例为70%(95% CI 0.57-0.82)。
- 未治疗患者2-3个月的平均听力增益为24.0 dB HL(95% CI 2.65-45.37)。
临床怎么用
- 作者认为观察到的自然史提示患者可在无主动治疗下恢复部分听力。
- 作者认为本文数据可作为历史对照数据用于重新审视既往研究结果及设计未来临床试验。
- 作者认为未治疗/安慰剂组有统计学意义的平均听力增益为未来安慰剂研究提供了伦理依据。
- 作者呼吁开展多机构、随机、双盲、安慰剂对照试验以提供基于科学的治疗指导。
局限性
- 研究间异质性为中等,报告了多种结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Although corticosteroids and other treatments for idiopathic sudden sensorineural hearing loss (ISSNHL) have been described, understanding its prognosis without intervention provides valuable information for patient management. The objective of this study is to provide a comprehensive, quantitative statistical analysis of the natural history of untreated idiopathic sudden sensorineural hearing loss (ISSNHL). STUDY TYPE AND DESIGN: A systematic review and meta-analyses. METHODS: Two independent searches of PubMed, Scopus, Web of Science, and Cochrane Library databases up to June 30, 2022, were performed. Adults with idiopathic sudden sensorineural hearing loss who received placebo or were untreated and had audiometric outcome measures in all study types were reviewed. These data indicative of the natural history of ISSNHL were analyzed, as were study characteristics related to risk of bias. Heterogeneity as assessed via I2 and random effects analyses were performed. RESULTS: Six studies meeting the inclusion criteria yielded 319 untreated patients whose natural history could be assessed. Heterogeneity among studies was moderate, with a variety of reported outcomes. A hearing improvement of at least 30 dB HL was observed in 36% (95% CI 0.28-0.44) of untreated patients, and of at least 10 dB HL was observed in 70% (95% CI 0.57-0.82) of untreated patients at 3 months. The mean hearing gain among untreated patients was 24.0 dB HL (95% CI 2.65-45.37) at 2-3 months. CONCLUSIONS: The observed natural history of ISSNHL suggests that patients can regain some hearing without active treatment. In the absence of future studies collecting prospective natural history data from untreated or placebo-treated ISSNHL patients, the data presented here provide the best available historical control data for reconsideration of results in past ISSNHL studies, as well as a roadmap for design and interpretation of future ISSNHL treatment clinical trials. Furthermore, knowing there is a statistically significant mean hearing gain of 24.0 dB HL in the untreated/placebo group provides an ethical basis for future placebo study of ISSNHL. The current status on ISSNHL management calls for a multi-institutional, randomized, double-blind placebo-controlled trial with validated outcome measures to provide science-based treatment guidance. Laryngoscope, 134:S1-S15, 2024.
引用
- Ying YM, Tseng CC, Shin J, et al. Natural History of Untreated Idiopathic Sudden Sensorineural Hearing Loss. Laryngoscope. 2024. PMID: 38808803. doi:10.1002/lary.31474
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。